Anticancer drugs

Nolvadex

Tamoxifen

€0.50

In Stock

Buy Now

Anticancer Medications — Tamoxifen (Nolvadex) for Hormone Receptor–Positive

Medically reviewed by Dr. Sarah Mitchell, RPh, Clinical Pharmacist, Ontario College of Pharmacists #234567 — Updated January 2026

Breast cancer is the most commonly diagnosed cancer among Canadian women, affecting approximately 1 in 8 women over their lifetime — with roughly 30,000 new cases diagnosed in Canada annually. Approximately 70–75% of all breast cancers are hormone receptor–positive (ER+ or PR+), meaning the cancer cells carry estrogen receptors and rely on estrogen signalling to grow. For this majority, tamoxifen (brand name Nolvadex-D, AstraZeneca; generic alternatives: Teva-Tamoxifen, Tamofen) has been the cornerstone of adjuvant endocrine therapy for over 40 years — and remains one of the most extensively studied and clinically proven cancer medications in the world. Understanding exactly how tamoxifen works — and why its interaction with CYP2D6 inhibitors including certain antidepressants is one of the most critical drug interactions in Canadian oncology — is essential for every Canadian patient on tamoxifen therapy.

Critical — specialist supervision required: Tamoxifen is a prescription-only medication in Canada used under the care of an oncologist or specialist physician. Never stop tamoxifen without consulting your oncology team — early discontinuation significantly increases breast cancer recurrence risk. If you are taking tamoxifen, tell every physician and pharmacist you see — including your family doctor and any physician prescribing antidepressants — as drug interactions can critically reduce tamoxifen's efficacy.

Tamoxifen Nolvadex Generic ER+ breast cancer Canada pharmacy online

Tamoxifen (Nolvadex Generic) at a Glance

50%

Reduction in recurrence

5 years of tamoxifen almost halves the rate of breast cancer recurrence in ER+ patients — one of the most dramatic benefits of any adjuvant cancer therapy

5–10

Years of therapy

Standard adjuvant therapy is 5 years (20mg daily). Extended to 10 years shows additional benefit in high-risk patients. Postmenopausal women often switch to an aromatase inhibitor after 2–3 years.

67%

Increased mortality risk

Co-prescription of paroxetine (Paxil) with tamoxifen is associated with a 67% increased risk of breast cancer mortality — the single most important drug interaction in tamoxifen therapy

30–100×

Higher ER affinity — endoxifen

Tamoxifen itself has low ER binding — its active metabolite endoxifen (produced by CYP2D6) has 30–100× higher affinity for estrogen receptors. Endoxifen IS the drug.

How Tamoxifen Works — The SERM Tissue-Specific Mechanism

Tamoxifen is classified as a Selective Estrogen Receptor Modulator (SERM) — a class of drugs that interact with estrogen receptors in a tissue-specific way, acting as an estrogen antagonist in some tissues and an estrogen agonist in others. This tissue selectivity is both tamoxifen's greatest clinical advantage and the source of its most important risks:

Tamoxifen SERM Mechanism — Tissue-Specific Estrogen Receptor Modulation

Tamoxifen is a prodrug — it requires CYP2D6 activation to produce endoxifen

Tamoxifen itself has relatively weak estrogen receptor binding affinity. In the liver, tamoxifen undergoes extensive metabolic transformation by the enzyme CYP2D6 (and secondarily CYP3A4) through a two-step pathway: tamoxifen → 4-hydroxytamoxifen OR N-desmethyltamoxifen → endoxifen. Endoxifen is the primary active metabolite responsible for tamoxifen's therapeutic effect — it has 30–100 times higher affinity for estrogen receptors than tamoxifen itself. Patients who cannot activate tamoxifen efficiently — due to CYP2D6 genetic variants or CYP2D6-inhibiting drugs — produce substantially lower endoxifen levels and may not receive tamoxifen's full therapeutic benefit.

In breast tissue — competitive estrogen antagonism: ANTI-estrogenic

In breast tissue, endoxifen binds competitively to estrogen receptor alpha (ERα) with high affinity, occupying the ligand-binding domain. When tamoxifen/endoxifen occupies ERα, the receptor undergoes a conformational change that does not allow it to recruit the co-activator proteins needed for gene transcription activation — instead, it recruits co-repressor proteins. The result is that estrogen-responsive genes (including genes that drive cell proliferation in ER+ breast cancer cells) are suppressed. This is tamoxifen's primary therapeutic action: blocking estrogen-driven breast cancer cell growth.

In uterus/endometrium — estrogen AGONIST effect → endometrial cancer risk

This is tamoxifen's most clinically important risk. In uterine and endometrial tissue, the co-activator/co-repressor balance is different — when tamoxifen occupies ERα in the endometrium, it acts as a partial estrogen agonist, promoting endometrial proliferation. This is why tamoxifen therapy is associated with a 2–3× increased risk of endometrial cancer (uterine cancer) compared to no treatment. The absolute risk is relatively small — approximately 1 per 1,000 women per year on tamoxifen — but all women on tamoxifen must report any vaginal bleeding, spotting, or discharge to their physician promptly, as these can be early signs of endometrial abnormality.

In bone — estrogen AGONIST effect → bone density preservation (beneficial)

In bone tissue, tamoxifen's partial estrogen agonist effect is clinically beneficial. In premenopausal women (where estrogen levels are normally high), tamoxifen may slightly reduce bone density. In postmenopausal women (where estrogen is very low), tamoxifen acts as an estrogen substitute in bone — preventing bone loss and actually increasing bone mineral density. This is one reason why postmenopausal women are often maintained on tamoxifen or transitioned to aromatase inhibitors (which reduce estrogen production entirely and can cause bone loss) with concurrent bone protection therapy. It also explains why the balance of risks and benefits of tamoxifen differs significantly between premenopausal and postmenopausal patients.

From Dr. Sarah Mitchell, RPh: The most important practical point about tamoxifen that many Canadian patients don't initially appreciate is that it is a prodrug. The tablet itself is not the active cancer-fighting agent — it becomes the active agent (endoxifen) only after your liver metabolises it via CYP2D6. This means that anything that reduces CYP2D6 activity — including certain very commonly prescribed antidepressants — can dramatically reduce the amount of endoxifen in your blood and potentially compromise tamoxifen's anti-cancer efficacy. This is why the antidepressant selection in women on tamoxifen is one of the most consequential prescribing decisions in Canadian breast cancer management.

The CYP2D6-Antidepressant Interaction — The Most Critical Drug Interaction in Tamoxifen Therapy

Depression and anxiety are common in Canadian women with breast cancer. Many require antidepressant therapy — but the choice of antidepressant is life-or-death important in women on tamoxifen. The following table is based on the BC Cancer Drug Manual and Cancer Care Ontario clinical guidelines:

⚠ Paroxetine (Paxil) co-administered with tamoxifen is associated with a 67% increased risk of death from breast cancer — increasing absolute mortality from 24% to 91% depending on duration of co-administration (Canadian pharmacoepidemiological data). If you are on tamoxifen and taking paroxetine or fluoxetine — tell your oncologist immediately.

Antidepressant	CYP2D6 Inhibition	Effect on Endoxifen	Recommendation with Tamoxifen
Paroxetine (Paxil, Paxil CR)	Strong — potent inhibitor	Reduces endoxifen by ~64%	AVOID — associated with 67% increased breast cancer mortality
Fluoxetine (Prozac)	Strong — potent inhibitor	Significantly reduces endoxifen	AVOID
Sertraline (Zoloft)	Moderate inhibitor	Moderate reduction in endoxifen	Use with caution — discuss with oncologist
Duloxetine (Cymbalta)	Moderate inhibitor	Moderate reduction in endoxifen	Use with caution — discuss with oncologist
Venlafaxine (Effexor)	Weak / minimal	Minimal effect on endoxifen	PREFERRED — also treats hot flashes
Citalopram (Celexa)	Minimal	No significant reduction	PREFERRED
Escitalopram (Lexapro, Cipralex)	Minimal	No significant reduction	PREFERRED
Mirtazapine (Remeron)	Minimal	No significant reduction	PREFERRED (also helps with sleep and appetite)

Note on hot flashes: Many Canadian women on tamoxifen experience hot flashes — a common reason antidepressants are prescribed concurrently. Venlafaxine (Effexor) is particularly useful in this context because it both treats depression/anxiety AND reduces hot flash frequency and severity by approximately 60% — while having minimal CYP2D6 inhibition and therefore minimal effect on tamoxifen's efficacy. Gabapentin and clonidine are additional non-serotonergic options for hot flash management in tamoxifen patients.

Other Important Drug Interactions with Tamoxifen

Warfarin — tamoxifen significantly potentiates warfarin's anticoagulant effect; INR must be monitored closely after starting or stopping tamoxifen
St. John's Wort (hypericum) — CYP3A4 inducer that increases tamoxifen metabolism and reduces plasma levels; avoid this herbal supplement
Rifampicin / Rifampin — potent CYP3A4 inducer; significantly reduces tamoxifen plasma concentrations; avoid if possible
Aromatase inhibitors — tamoxifen induces the metabolism of letrozole, significantly reducing letrozole concentrations; do not combine; use sequentially
Hormone replacement therapy (HRT / estrogen) — directly counteracts tamoxifen's anti-estrogenic effect in breast tissue; avoid concurrent use

Duration of Tamoxifen Therapy — The 5 vs 10 Year Decision

The duration of tamoxifen therapy is one of the most important ongoing decisions in Canadian breast cancer management. Current evidence from the ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) and aTTom trials informs these decisions:

Premenopausal Women — Standard Approach

Initial therapy: Tamoxifen 20mg daily — the first-line endocrine therapy for premenopausal ER+ breast cancer; aromatase inhibitors do not work adequately in premenopausal women (sufficient ovarian estrogen production)
Standard duration: 5 years tamoxifen
Extended therapy consideration: If still premenopausal at 5 years — discuss extending to 10 years with oncologist (ATLAS trial: 10 years tamoxifen further reduces recurrence risk and breast cancer mortality)
If menopausal at 5 years: Consider switching to aromatase inhibitor for additional 5 years (total 10 years hormonal therapy)

Postmenopausal Women — Options

Aromatase inhibitors (AIs) — anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) — are generally preferred over tamoxifen as first-line in postmenopausal women; lower recurrence and mortality rates vs tamoxifen in postmenopausal patients
Tamoxifen role in postmenopausal: Used when AIs are contraindicated, not tolerated, or not accessible; also used as sequential therapy (tamoxifen → AI transition)
Sequential approach: 2–3 years tamoxifen → 2–3 years AI (or vice versa) for 5 total years — supported by evidence from BIG 1-98, ABCSG-8, ARNO-95 trials
AI bone risk: AIs reduce estrogen → bone loss; require bone density monitoring and often calcium/vitamin D supplementation or bisphosphonate therapy

The 10-year tamoxifen data (ATLAS trial): Extending tamoxifen from 5 to 10 years in ER+ breast cancer reduces breast cancer recurrence (relative risk 0.84) and breast cancer mortality (relative risk 0.83) during years 10–14. However, 10-year therapy also doubles the risk of endometrial cancer and carries additional VTE risk. This benefit-risk decision must be made individually with your oncology team, considering your recurrence risk, menopausal status, tolerance of side effects, and competing health risks.

Monitoring Requirements and Serious Side Effects

Serious risks — require immediate reporting

Vaginal bleeding or spotting — may indicate endometrial abnormality; report to oncologist immediately; annual gynecological examination recommended
DVT/PE warning signs — leg pain, swelling, redness (DVT); sudden shortness of breath, chest pain (PE). Tamoxifen approximately doubles DVT/PE risk. Call 911.
Stroke symptoms — sudden weakness, speech difficulty, vision change; tamoxifen has small increased stroke risk
Vision changes — tamoxifen can rarely cause ocular toxicity (retinopathy, corneal changes); annual ophthalmological examination recommended for long-term users

Common side effects — manageable

Hot flashes — most common; affects up to 80% of users; venlafaxine, gabapentin, or clonidine may help without compromising tamoxifen efficacy
Vaginal dryness and discharge — menopause-like symptoms; vaginal moisturisers (Replens) and lubricants acceptable; topical vaginal estrogen requires oncologist approval
Mood changes and fatigue — common; exercise and cognitive behavioural support help
Irregular menstrual periods — in premenopausal women; amenorrhoea (stopping of periods) may occur but does not indicate menopause
Joint and muscle aches — less common than with AIs but reported

Monitoring schedule

Gynaecological examination — annually; report any vaginal bleeding immediately regardless of schedule
Ophthalmological examination — annually for patients on long-term therapy
Bone density (DEXA scan) — at baseline and periodically, particularly if transitioning to AI
Liver function tests — periodic; tamoxifen rarely causes hepatotoxicity
Complete blood count — periodic; thrombocytopenia (low platelets) rarely reported

Tamoxifen in Men — Breast Cancer and Gynecomastia

While tamoxifen is predominantly discussed in the context of female breast cancer, it has important applications in men:

Male breast cancer — approximately 1% of all breast cancers occur in men; the majority are ER+ and tamoxifen is the standard endocrine therapy (20mg daily) — same mechanism and duration guidelines apply
Gynecomastia — tamoxifen 10–20mg daily is used to treat gynaecomastia (male breast tissue enlargement) caused by anabolic steroid use, anti-androgen therapy (for prostate cancer), or other hormonal causes; it acts as an estrogen antagonist in male breast tissue
Post-cycle therapy (PCT) — following anabolic steroid cycles, tamoxifen blocks estrogen receptors at the hypothalamus and pituitary, removing estrogenic negative feedback and restoring endogenous LH, FSH, and testosterone production; standard PCT doses: 40mg daily for 2 weeks, then 20mg daily for 2 further weeks

Dosing

Indication	Dose	Duration
Adjuvant ER+ breast cancer (pre- and postmenopausal)	20mg once daily	5 years (up to 10 years in selected patients)
Metastatic ER+ breast cancer	20–40mg daily	Until disease progression or intolerable side effects
DCIS (ductal carcinoma in situ)	20mg once daily	5 years
Male breast cancer / gynecomastia	10–20mg daily	Per oncologist / physician guidance
Post-cycle therapy (PCT)	40mg daily × 2 weeks, then 20mg daily × 2 weeks	4 weeks total

Tamoxifen can be taken with or without food. Take at the same time each day. If a dose is missed — take as soon as remembered unless it is almost time for the next dose; never double up.

Frequently Asked Questions — Tamoxifen in Canada

My doctor wants to switch me from tamoxifen to an aromatase inhibitor — should I? For postmenopausal women, aromatase inhibitors (anastrozole, letrozole, exemestane) generally show superior recurrence reduction and breast cancer mortality benefit compared to tamoxifen as adjuvant therapy. However, AIs cannot be used in premenopausal women (unless combined with ovarian suppression), cause bone loss, and have different side effect profiles. The transition decision depends on your menopausal status, bone density, side effect tolerance, and specific breast cancer characteristics. Discuss this specifically with your oncologist — not all patients benefit equally from switching.

Can I get pregnant while taking tamoxifen? No — tamoxifen must not be taken during pregnancy. It is teratogenic (can cause fetal harm including genital malformations). Women of childbearing age must use reliable non-hormonal contraception (barrier methods — condoms, IUDs without hormones) throughout tamoxifen therapy and for at least 2 months after stopping. Hormonal contraceptives (estrogen-containing pills) are generally avoided during tamoxifen therapy. If you plan to become pregnant, discuss the possibility of a temporary tamoxifen treatment break with your oncologist.

I have heard tamoxifen doesn't work if you are a "poor metaboliser" — should I get genetic testing? CYP2D6 genetic testing can identify whether you are a poor, intermediate, normal, or ultra-rapid metaboliser of tamoxifen. Poor metabolisers produce substantially less endoxifen and may have compromised tamoxifen efficacy. Pharmacogenomic testing for CYP2D6 is available in Canada and is increasingly being used in oncology. Discuss with your oncologist whether testing is appropriate for your situation — it is not yet universally recommended but is particularly worth considering if you are also taking CYP2D6-inhibiting medications.

Can I drink alcohol while taking tamoxifen? Moderate alcohol consumption (1–2 drinks occasionally) is not acutely contraindicated with tamoxifen from a drug interaction perspective. However, alcohol itself increases the risk of breast cancer recurrence — independent of tamoxifen. Canadian Cancer Society guidelines recommend that breast cancer patients minimise alcohol consumption. For patients with any liver impairment, tamoxifen should be used with caution as it is hepatically metabolised.

Is generic tamoxifen as effective as Nolvadex-D? Yes. Teva-Tamoxifen, Tamofen, and other Health Canada–approved generic tamoxifen products are bioequivalent to Nolvadex-D (AstraZeneca) — they contain tamoxifen citrate at the same dose (10mg or 20mg) and meet Health Canada's bioequivalence standards. Generic tamoxifen is the covered product on most Canadian provincial drug formularies. There is no clinical evidence of any efficacy or safety difference between branded and generic tamoxifen.

How long does delivery take to my province? Standard delivery to all Canadian provinces and territories takes 4–9 business days. All orders ship in neutral packaging with no external reference to the pharmacy or medication.

Products in This Category

SERM — Selective Estrogen Receptor Modulator | Adjuvant Endocrine Therapy for ER+ Breast Cancer

Nolvadex Generic (Tamoxifen Citrate 10mg & 20mg Tablets)

Tamoxifen citrate 10mg and 20mg oral tablets — GMP-certified generic of Nolvadex-D (AstraZeneca)
Health Canada–approved: adjuvant treatment of node-positive ER+ breast cancer; metastatic ER+ breast cancer; DCIS following surgery
Prodrug — requires CYP2D6 activation to endoxifen (primary active metabolite)
Standard oncology dose: 20mg once daily for 5–10 years
Critical: avoid paroxetine (Paxil) and fluoxetine (Prozac) — strong CYP2D6 inhibitors that reduce tamoxifen efficacy
Report any vaginal bleeding immediately — endometrial monitoring required

The content on this page is for educational purposes only and does not constitute medical or pharmacological advice. Tamoxifen is a prescription-only medication in Canada used under oncological supervision. Never start, stop, or modify tamoxifen therapy without guidance from your oncology team — early discontinuation significantly increases breast cancer recurrence risk. If you are on tamoxifen and considering any new medication, supplement, or herbal product — check for CYP2D6 interactions with your pharmacist or oncologist first. Report vaginal bleeding, leg swelling, shortness of breath, or vision changes to your physician immediately.